Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,383 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute resistance to BET inhibitors remodels compensatory transcriptional programs via p300 coactivation.
Shah V, Giotopoulos G, Osaki H, Meyerhöfer M, Meduri E, Gallego-Crespo A, Behrendt MA, Saura-Pañella M, Tarkar A, Schubert B, Yun H, Horton SJ, Agrawal-Singh S Dr, Hähnel PS, Basheer F, Lugo D, Eleftheriadou I, Barbash O, Dhar A, Kühn M, Guezguez B, Theobald M, Kindler T, Gallipoli P, Yeh PS, Dawson MA, Prinjha RK, Huntly BJ, Sasca D. Shah V, et al. Among authors: kuhn m. Blood. 2024 Dec 9:blood.2022019306. doi: 10.1182/blood.2022019306. Online ahead of print. Blood. 2024. PMID: 39651888
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM, Steiner M, Rausch J, Sasca D, Schönfeld J, Kunz K, Taubert MC, McGeehan GM, Chen CW, Mupo A, Hähnel P, Theobald M, Kindler T, Koche RP, Vassiliou GS, Armstrong SA, Kühn MWM. Dzama MM, et al. Among authors: kuhn mwm. Blood. 2020 Nov 19;136(21):2442-2456. doi: 10.1182/blood.2020005037. Blood. 2020. PMID: 32589720 Free PMC article.
Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax.
Rausch J, Dzama MM, Dolgikh N, Stiller HL, Bohl SR, Lahrmann C, Kunz K, Kessler L, Echchannaoui H, Chen CW, Kindler T, Döhner K, Burrows F, Theobald M, Sasca D, Kühn MWM. Rausch J, et al. Among authors: kuhn mwm. Haematologica. 2023 Oct 1;108(10):2837-2843. doi: 10.3324/haematol.2022.282160. Haematologica. 2023. PMID: 37102614 Free PMC article. No abstract available.
Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia.
Krönke J, Bullinger L, Teleanu V, Tschürtz F, Gaidzik VI, Kühn MW, Rücker FG, Holzmann K, Paschka P, Kapp-Schwörer S, Späth D, Kindler T, Schittenhelm M, Krauter J, Ganser A, Göhring G, Schlegelberger B, Schlenk RF, Döhner H, Döhner K. Krönke J, et al. Among authors: kuhn mw. Blood. 2013 Jul 4;122(1):100-8. doi: 10.1182/blood-2013-01-479188. Epub 2013 May 23. Blood. 2013. PMID: 23704090 Free article.
Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia.
Albinger N, Pfeifer R, Nitsche M, Mertlitz S, Campe J, Stein K, Kreyenberg H, Schubert R, Quadflieg M, Schneider D, Kühn MWM, Penack O, Zhang C, Möker N, Ullrich E. Albinger N, et al. Among authors: kuhn mwm. Blood Cancer J. 2022 Apr 13;12(4):61. doi: 10.1038/s41408-022-00660-2. Blood Cancer J. 2022. PMID: 35418180 Free PMC article.
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin.
Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider I, Corbacioglu A, Gaidzik VI, Meid A, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K. Rücker FG, et al. Among authors: kuhn mwm. Blood Adv. 2024 Dec 10;8(23):6067-6080. doi: 10.1182/bloodadvances.2024013758. Blood Adv. 2024. PMID: 39348668 Free PMC article.
Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications.
Döhner H, Weber D, Krzykalla J, Fiedler W, Wulf G, Salih H, Lübbert M, Kühn MWM, Schroeder T, Salwender H, Götze K, Westermann J, Fransecky L, Mayer K, Hertenstein B, Ringhoffer M, Tischler HJ, Machherndl-Spandl S, Schrade A, Paschka P, Gaidzik VI, Theis F, Thol F, Heuser M, Schlenk RF, Bullinger L, Saadati M, Benner A, Larson R, Stone R, Döhner K, Ganser A. Döhner H, et al. Among authors: kuhn mwm. Blood Adv. 2022 Sep 27;6(18):5345-5355. doi: 10.1182/bloodadvances.2022007223. Blood Adv. 2022. PMID: 35486475 Free PMC article. Clinical Trial.
Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing.
Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Krönke J, Kühn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, Schlenk RF, Rücker FG, Döhner H, Lottaz C, Döhner K, Bullinger L. Dolnik A, et al. Among authors: kuhn mw. Blood. 2012 Nov 1;120(18):e83-92. doi: 10.1182/blood-2011-12-401471. Epub 2012 Sep 13. Blood. 2012. PMID: 22976956 Free article.
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations.
Edelmann J, Holzmann K, Miller F, Winkler D, Bühler A, Zenz T, Bullinger L, Kühn MW, Gerhardinger A, Bloehdorn J, Radtke I, Su X, Ma J, Pounds S, Hallek M, Lichter P, Korbel J, Busch R, Mertens D, Downing JR, Stilgenbauer S, Döhner H. Edelmann J, et al. Among authors: kuhn mw. Blood. 2012 Dec 6;120(24):4783-94. doi: 10.1182/blood-2012-04-423517. Epub 2012 Oct 9. Blood. 2012. PMID: 23047824 Free article.
1,383 results